AstraZeneca is navigating the final regulatory hurdles for an alternative delivery method of its lupus therapy. As reported by PharmaBiz.com, the company received a complete response letter from the FDA regarding its application for a subcutaneous formulation of Saphnelo (anifrolumab) but has since submitted additional information to address the agency’s questions. A regulatory decision is anticipated within the first half of 2026.
A Path Forward for Lupus Patients
The subcutaneous formulation represents a significant shift in how patients with systemic lupus erythematosus could manage their disease. Currently, the intravenous version requires hospital or clinic visits for infusions, a substantial burden for patients managing a chronic, multisystem autoimmune condition. A self-administered injection offers potential advantages in convenience and quality of life, particularly important for the millions globally living with this debilitating disease.
European Success Paves the Way
The European Union granted approval for subcutaneous Saphnelo in December 2025, validating the subcutaneous approach. The underlying clinical evidence comes from the TULIP-SC trial, a randomized, placebo-controlled phase III study that enrolled 367 patients with moderate to severe lupus. Participants received either 120 milligrams of subcutaneous anifrolumab or placebo via pre-filled syringes while continuing standard lupus medications.
The trial achieved its primary goal, demonstrating that the subcutaneous formulation reduced disease activity by week 52. Importantly, the full analysis published in Arthritis & Rheumatology confirmed these findings held across the complete patient population studied.
The Burden of Untreated Lupus
The approval matters because lupus exacts a substantial toll on patients. Over 3.4 million people worldwide contend with this condition, which causes the immune system to attack healthy tissue, triggering joint pain, skin rashes, fatigue, and potentially affecting vital organs. The disease disproportionately impacts women and carries serious long-term consequences, approximately half of lupus patients experience irreversible organ damage within five years of diagnosis, largely driven by necessary but damaging corticosteroid therapy.
Even modest reductions in steroid dosing—as little as one milligram daily—can meaningfully lower organ damage risk, making therapies that reduce disease activity particularly valuable.
Clinical Trial Design
The TULIP-SC trial methodology reinforced the robustness of findings. A planned interim analysis examined the first 220 patients who reached the 52-week mark, allowing early assessment before the full cohort completed the study. Disease improvement was measured using BICLA, a rigorous assessment requiring improvement across all affected organ systems with no new disease flares—a stringent endpoint reflecting meaningful clinical benefit.
The study also included an extended follow-up period, providing longer-term safety data essential for regulatory decision-making.
How It Works
Saphnelo operates by blocking type I interferon signaling, a pathway central to lupus-driven inflammation. The intravenous version already enjoys established credentials, becoming the first biologic demonstrating remission in lupus from a multi-year placebo-controlled trial. This mechanism continues to undergo investigation in related conditions including cutaneous lupus, myositis, systemic sclerosis, and lupus nephritis.
With over 40,000 patients globally already using the intravenous formulation, subcutaneous availability could expand treatment accessibility and potentially improve medication adherence by eliminating clinic visit requirements for administration.
